Analysis of Differentially Expressed Genes in Schizophrenia Based on Bioinformatics and Corresponding Mrna Expression Levels DOI
Shikun Tian,

Meiting Liu,

Xiaoying Liu

et al.

Published: Jan. 1, 2024

Language: Английский

Analysis of differentially expressed genes in schizophrenia based on bioinformatics and corresponding mRNA expression levels DOI Creative Commons

Meiting Liu,

Shiqi Tian, Xiaoying Liu

et al.

Schizophrenia Research, Journal Year: 2025, Volume and Issue: 280, P. 22 - 29

Published: April 10, 2025

Language: Английский

Citations

0
Dysregulation of miRNAs in Schizophrenia in an Egyptian Patient Population DOI

Noha Adly,

Dalia Khalifa,

Shaimaa Abdel-Ghany

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Abstract Schizophrenia (SZ) is a complex neuropsychiatric disorder influenced by genetic, environmental, and epigenetic factors, including miRNA dysregulation. This study explored the diagnostic therapeutic potential of miRNAs in SZ, focusing on seven key miRNAs: miR-137-3p, miR-34a-5p, miR-432-5p, miR-130b-3p, miR-346, miR-195-5p, miR-103a-3p. Results revealed significant dysregulation miR-103a-3p, highlighting their relevance to SZ pathology. Upregulation miR-137-3p correlated with enhanced cognitive performance, as evidenced improved scores Wisconsin Card Sorting Test (WCST) Trail Making B (TMT-B). Conversely, miR-195-5p miR-346 were strongly associated processing speed, while miR-103a-3p downregulation was linked reduced conceptual flexibility. Cluster analyses demonstrated that expression levels varied significantly based antipsychotic treatment receptor targeting, suggesting regulatory effects medication. Importantly, measured PBMCs, feasibility non-invasive biomarkers. The underscores value miRNAs, offering promising avenue for early detection personalized interventions SZ. Future research should validate these findings across diverse cohorts investigate miRNA-based strategies. By integrating profiling into clinical practice, this provides foundation advancing precision medicine management.

Language: Английский

Citations

0
MicroRNA dysregulation in glutamate and dopamine pathways of schizophrenia: From molecular pathways to diagnostic and therapeutic approaches DOI

Parya Alizadeh Khosroshahi,

Mohammad Ghanbari

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Journal Year: 2024, Volume and Issue: 135, P. 111081 - 111081

Published: July 14, 2024

Language: Английский

Citations

0
Extended range proteomic analysis of blood plasma from schizophrenia patients DOI Creative Commons
Denis V. Petrovskiy, Tatiana V. Butkova,

Kirill S. Nikolsky

et al.

Frontiers in Molecular Biosciences, Journal Year: 2024, Volume and Issue: 11

Published: Nov. 21, 2024

The high prevalence of schizophrenia worldwide makes it necessary to proceed from subjective assessment patient's clinical symptoms in diagnosis making searching for circulating blood biomarkers. On the one hand, molecular markers and targets therapeutics will make possible refine detail mechanisms pathology development, while on other offer new opportunities elaborating novel approaches disease enhance efficacy timeliness drug therapy.

Language: Английский

Citations

0
Analysis of Differentially Expressed Genes in Schizophrenia Based on Bioinformatics and Corresponding Mrna Expression Levels DOI
Shikun Tian,

Meiting Liu,

Xiaoying Liu

et al.

Published: Jan. 1, 2024

Language: Английский

Citations

0